Sysmex America, Chicago, has joined the Clinical Lab 2.0 movement to support collaboration around value-based healthcare. Sysmex is providing a grant for a multiinstitutional demonstration project to develop actionable clinical strategies for the early detection, intervention, and prevention of anemia.
Clinical Lab 2.0 is an initiative by the Project Santa Fe Foundation to help develop the evidence base for the valuation of clinical laboratory services in the next era of global healthcare. Sysmex America is the first corporate sponsor in this globally focused, nonexclusive, and nonrestrictive partnership. The participants in Project Santa Fe represent major diagnostics organizations that want to explore laboratory-driven innovations and test their global value.
According to Sysmex, population health management is emerging as a way to support value-based healthcare. The approach aggregates patient data across multiple health information technology resources and analyzes the data to produce a single, actionable patient record, enabling care providers to improve both clinical and financial outcomes.
Anemia is an independent predictor of an individual’s morbidity and mortality when compared with healthy patient populations. Numerous studies have shown the negative impact of anemia on clinical outcomes, which in turn increases healthcare costs. Practitioners can screen for anemia using a routine complete blood count and effectively treat patients before their symptoms become worse.
Healthcare systems that are better able to manage anemia can significantly reduce patient complications along with their associated costs. Clinical Laboratory 2.0 encourages laboratories to aggregate and leverage their clinical data to support preventive care. Identifying at-risk populations, pinpointing gaps in care, and finding high-risk patients enables early intervention that can ultimately bring down healthcare costs.
“Laboratory medicine is able to provide meaningful clinical diagnostic insights for population health initiatives that result in improved short- and long-term patient outcomes and drive cost-effective care,” says Andy Hay, chief operating officer of Sysmex America. “Opportunities include data analysis with longitudinal laboratory data, identification of patient-specific targeted interventions, and development of clinical decision support tools.”
“The Clinical Lab 2.0 movement, with its critical measurable and actionable attributes, promotes the clinical and business model of the future for clinical laboratories,” says Khosrow Shotorbani, president and executive director of the Project Santa Fe Foundation. “The Clinical Lab 2.0 movement is not possible without key industry partners like Sysmex America. We are pleased to have their support in helping us move closer to reshaping how laboratory information is used to improve healthcare.”